Metastasis is a major clinical challenge for cancer treatment. Emerging evidence suggests that aberrant epigenetic modifications contribute significantly to tumor formation and progression. However, the drivers and roles of such epigenetic changes in tumor metastasis are still poorly understood. Using bioinformatic analysis of human breast cancer gene-expression data sets, we identified histone demethylase RBP2 as a putative mediator of metastatic progression. By using both human breast cancer cells and genetically engineered mice, we demonstrated that RBP2 is critical for breast cancer metastasis to the lung in multiple in vivo models. Mechanistically, RBP2 promotes metastasis as a pleiotropic positive regulator of many metastasis genes, including TNC. In addition, RBP2 loss suppresses tumor formation in MMTV-neu transgenic mice. These results suggest that therapeutic targeting of RBP2 is a potential strategy for inhibition of tumor progression and metastasis.
INTRODUCTION
In the United States, breast cancer is the most common cancer and the second leading cause of cancer death in women (DeSantis et al., 2011) . Advanced breast cancer is associated with significant mortality because it metastasizes to vital organs, primarily to lung, brain, and bone (Bos et al., 2009; Kang et al., 2003; Minn et al., 2005 Minn et al., , 2007 . There are still limited treatment options for patients with metastatic breast cancer. Thus, it is critical to identify and validate novel drug targets for the development of effective therapies.
Tumor metastasis is a multistage process that includes local invasion, intravasation, survival in the circulation, extravasation, and colonization in distant organs (Nguyen et al., 2009a; Sethi and Kang, 2011) . During this process, cancer cells must overcome various physiological barriers and adapt to foreign environments. This requires the coordinated modulation of pleiotropic genetic programs at different stages of tumor progression (Brabletz, 2012; Peinado et al., 2012) . It is conceivable that to achieve this kind of plasticity, reversible transcription programs may be required in addition to somatic genetic alterations. Consistent with this idea, many epigenetic regulators have been reported to play critical roles in this process (Nguyen and Massagué , 2007) . For example, histone H3K27 methyltransferase EZH2 and histone demethylase JMJD2C (also known as KDM4C) were shown to promote tumor progression and metastasis (Luo et al., 2012; Min et al., 2010; Varambally et al., 2002) . In contrast, histone H3K4 demethylase LSD1 was reported to inhibit breast cancer metastasis (Wang et al., 2009b) .
Breast cancer metastasis to different tissues is mediated in part by organ-specific metastasis genes, some of which are also highly expressed in the primary tumors. Some of these genes, such as MMP1 and CXCL1, provide growth advantages in both the primary and metastatic sites, whereas others, such as TNC and MMP2, promote aggressive growth only in the metastatic niche (Minn et al., 2007) . Despite their known functions, the mechanisms by which these genes are upregulated remain unknown. These gene products can be modulated individually or more broadly by pleiotropic regulators, including transcription factors and epigenetic regulators. Although transcription factors are difficult to target, epigenetic regulators are very attractive targets for cancer therapies, in part because epigenetic changes are reversible (Blair and Yan, 2012; Rodríguez-Paredes and Esteller, 2011) .
To identify epigenetic regulators that can be targeted in breast cancer metastasis, we conducted an unbiased bioinformatic analysis of human breast cancer data sets. We identified a strong association between the expression of histone demethylase RBP2 (also known as JARID1A and KDM5A) and breast cancer metastasis. RBP2 is a member of the JARID1 family histone demethylases, which catalyze the removal of methyl groups from tri-or dimethylated lysine 4 in histone H3 Christensen et al., 2007; Iwase et al., 2007; Klose et al., 2007; Lee et al., 2007; Secombe et al., 2007; Tahiliani et al., 2007; Yamane et al., 2007) . We showed that RBP2 positively regulates many metastasis-related genes, including TNC, which is required for metastatic colonization in the lungs. These findings were further validated in the MMTV-neu transgenic mouse model. Importantly, RBP2 promotes TNC expression and malignant invasion through a demethylase-independent mechanism. In summary, our findings suggest that RBP2 regulates a critical epigenetic switch that sets the stage for tumor metastasis and can be targeted to inhibit breast cancer progression and metastasis.
RESULTS

RBP2 Expression Is Strongly Associated with Breast Cancer Metastasis
To identify epigenetic regulators of breast cancer metastasis, we conducted an unbiased bioinformatic analysis of gene-expression profiles of mammary tumors from 533 breast cancer patients by using Kaplan-Meier Plotter, a meta-analysis-based biomarker assessment tool (Gyö rffy et al., 2010) . This analysis tool utilizes Affymetrix gene-expression profiling data, which have multiple probe sets for most genes. We examined the correlation between increased incidence of distant tumor metastasis with the gene-expression levels of a comprehensive list of targetable histone methylation and acetylation enzymes, including histone lysine methyltransferases (KMTs), histone lysine demethylases (KDMs), histone acetyltransferases (KATs), and histone deacetylases (HDACs). This analysis revealed that high mRNA levels of two enzymes, EZH2 and RBP2, correlated significantly with early and high incidence of tumor metastasis ( Figure 1A ; Table S1 ). Our approach was validated by the fact that EZH2 (only one probe available) was previously shown to promote invasion and metastasis of breast cancer cells (Kleer et al., 2003; Moore et al., 2013) . Two probes of RBP2 are present on the microarray platform, and both probes showed similar results ( Figures 1B and S1A ). RBP2 was previously found to promote tumorigenesis (Lin et al., 2011; Zeng et al., 2010) and drug resistance (Sharma et al., 2010) . However, the role of RBP2 in breast cancer metastasis has not been studied. Therefore, we focused on the role of RBP2 in breast cancer metastasis.
We validated the association of RBP2 expression with breast cancer metastasis using a large clinical data set, EMC286 (Figure S1B) . To determine whether the association of RBP2 expression with metastasis is subtype specific, we performed an independent analysis of estrogen receptor (ER)-positive (ER + ) and -negative (ER À ) patients. This revealed that RBP2 expression was strongly associated with metastasis in ER À patients in both the EMC286 and combined data sets, but was more weakly associated with metastasis in ER + patients only in the combined data set ( Figures 1C and S1C-S1I ). To further determine whether RBP2 can be an independent clinical indicator of metastasis, we conducted a Cox multivariate analysis of EMC286. Our analysis indicated that RBP2 was associated with tumor metastasis independently of ER, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status (Table S2) .
We then extended our analysis to the MDA-MB-231 and the 4T1 breast cancer cell line series. LM2 and 1833 cells were derived from ER À MDA-MB-231 human breast cancer cells by in vivo selection, and have increased metastatic activity to the lungs or bones, respectively, when compared with their parental cells (Kang et al., 2003; Minn et al., 2005) . The mouse mammary tumor cell lines 67NR, 168FARN, 4TO7, 66cl4, and 4T1 were isolated from a single spontaneous mammary tumor and have varying abilities to metastasize to the lungs (Aslakson and Miller, 1992) . Western blot analysis showed that RBP2 protein was expressed at a higher level in the more lung-metastatic LM2 cells compared with the bone-metastatic 1833 cells or the less metastatic parental MDA-MB-231 cells ( Figure 1D ). Furthermore, the expression levels of RBP2 correlated strongly with the metastatic capabilities of the 4T1 series, with RBP2 levels being highest in the most aggressive 4T1 cell line ( Figure 1D ). These results are consistent with our observation in patient samples that the RBP2 expression level correlated with increased metastatic potential.
RBP2 Is Critical for Prometastatic Gene Expression
To determine the roles of RBP2 in breast cancer, we transfected MDA-MB-231 cells with small interfering RNA (siRNA) against RBP2 or a siRNA control. We found that knockdown of RBP2 led to a global increase of H3K4me3 levels, suggesting that RBP2 is the major H3K4me3 demethylase in MDA-MB-231 cells (Figures S2A and S2B) . To determine the effects of RBP2 depletion on gene expression, we conducted microarray analysis of these cells and identified 176 upregulated and 212 downregulated genes after RBP2 knockdown (Table S3) . Next, we performed gene set enrichment analysis (GSEA) (Subramanian et al., 2005) to determine whether RBP2 loss causes alterations of known breast cancer organotropic metastasis gene signatures, including the lung-metastasis signature (LMS), bonemetastasis signature (BoMS), and brain-metastasis signature (BrMS) (Bos et al., 2009; Kang et al., 2003; Minn et al., 2005 Minn et al., , 2007 . These analyses revealed that RBP2 knockdown significantly decreased the expression of genes linked to breast cancer metastasis to the lungs (Figure 2A ). In contrast, there were See also Figure S1 and Tables S1 and S2. no significant changes in genes involved in breast cancer metastasis to the bone or brain in RBP2 knockdown cells ( Figure 2A , right panel). This result is consistent with our observations that RBP2 is highly expressed in the lung-metastatic LM2 cells, but not in the bone-metastatic 1833 cells. To confirm these results by real-time RT-PCR analysis, we selected TNC, SOX4, FSCN1, PDGFA, SERPINE2, and PLCB1, all of which have been implicated in breast cancer metastasis to the lungs (Minn et al., 2005 (Minn et al., , 2007 Tavazoie et al., 2008; Tiwari et al., 2013) . As expected, all of these genes were expressed at higher levels in LM2 cells compared with MDA-MB-231 cells ( Figure 2B ). Consistent with our GSEA results, RBP2 knockdown led to significant downregulation of all of these genes in MDA-MB-231 cells and most of these genes in LM2 cells ( Figure 2B ).
RBP2 Regulates Breast Cancer Cell Invasion through TNC
Invasion of tissue basement membranes is one of the key steps of metastasis. To dissect the roles of RBP2 in tumor metastasis, we first examined its role in invasion using Transwell invasion assays. LM2 cells, which expressed higher levels of RBP2, showed increased invasion ability compared with MDA-MB-231 cells ( Figure S3A ). Furthermore, we found that LM2 cells transfected with siRNAs against RBP2 showed a dramatic decrease in invasion ability compared with cells transfected with the control siRNAs ( Figures 3A and 3B) .
TNC, which encodes tenascin C, was the most significantly decreased metastasis gene in LM2 cells with RBP2 knockdown. TNC is an extracellular matrix protein that enhances cancer cell migration and invasion (Hancox et al., 2009; Nagaharu et al., 2011) . TNC also promotes colonization of breast cancer cells to the lungs and is a critical component of the metastatic niche in vivo (Oskarsson et al., 2011) . Therefore, we further examined the regulation of TNC as an output for epigenetic modulation of invasion by RBP2. We analyzed protein levels in the media of LM2 cells and confirmed that extracellular TNC protein production was also regulated by RBP2 ( Figure 3C ). Next, we examined the correlation of RBP2 and TNC expression in human primary breast tumors. Consistent with our data from the cell lines, ER À tumors with high levels of RBP2 expressed high levels of TNC ( Figure S3B ). See also Figure S2 and Table S3 .
Since we showed that TNC expression is regulated by RBP2, we next tested whether TNC is required for the proinvasive function of RBP2. To that end, we added recombinant TNC protein into the chambers in Transwell assays. The addition of TNC partially rescued the decreased invasion phenotype in RBP2 knockdown cells ( Figure 3D ), suggesting that regulation of invasion by RBP2 was at least partially due to the decrease of TNC expression in RBP2 knockdown cells.
RBP2 Promotes TNC Expression and Invasion in a Demethylase-Independent Manner
To dissect the mechanism by which RBP regulates gene expression and invasion, we reintroduced siRNA-resistant forms of RBP2 into RBP2 knockdown cells. Consistent with the idea that RBP2 is critical for TNC expression, restoration of wildtype RBP2 expression rescued the TNC level in RBP2 knockdown cells ( Figure 4A ). Interestingly, reintroduction of a histone demethylase-defective form of RBP2 (RBP2 H483A) also rescued the decrease of TNC ( Figure 4A ). Moreover, chromatin immunoprecipitation (ChIP) assays showed that knockdown of RBP2 in LM2 cells led to only a slightly decrease of H3K4me3 near the TNC transcriptional start site ( Figures S4A and S4B) . These results suggest that the demethylase activity of RBP2 is not required for TNC expression in LM2 cells.
To further investigate whether other RBP2 domains are required for TNC expression, we tested the effects of expressing RBP2 truncation mutants in LM2 cells transfected with an siRNA targeting 3 0 UTR of RBP2. We found that RBP2 mutants lacking either the N-or C-terminal domains failed to rescue TNC expression ( Figures 4B and S4C) , suggesting that the N-and C-terminal domains are required for TNC expression in LM2 cells. To determine if TNC is a direct target of RBP2, we performed ChIP assays using an anti-RBP2 antibody. Despite strong enrichment of RBP2 at the promoter of a known RBP2 target gene NDUFA9, we did not detect RBP2 binding at the TNC promoter (Figure S4D) . Hence, RBP2 does not regulate expression of TNC by modulating its promoter activity.
Next, we determined the abilities of wild-type and mutant RBP2 to promote invasion. Reintroduction of either wild-type or a demethylase-defective RBP2 in LM2 cells rescued the diminished cell invasion induced by RBP2 knockdown (Figure 4C) . In contrast, an N-terminal truncated form of RBP2 was unable to rescue the decreased invasion ability of LM2 cells caused by RBP2 knockdown ( Figure 4D ), suggesting that the N-terminal domains, but not the histone demethylase activity of RBP2, are required to promote cell invasion.
RBP2 Is Critical for Breast Cancer Metastasis to the Lungs In Vivo
To investigate the roles of RBP2 in metastasis in vivo, we generated LM2 cells with a scrambled small hairpin RNA (shRNA) control hairpin or stable knockdown of RBP2 using two independent shRNA hairpins. LM2 cells were engineered to express firefly luciferase (Minn et al., 2005) , which allows for live imaging of metastasis in vivo. Similar to our results from siRNA-mediated knockdown, LM2 cells with RBP2 stable knockdown secreted lower levels of TNC compared with the control cells ( Figure S5A ). Cells with stable RBP2 knockdown and their respective control cell line were then injected into the tail vein of NOD.SCID mice. Lung metastatic activity was assayed by bioluminescence imaging weekly, as well as by examination of the lungs at necropsy. RBP2 knockdown led to an approximately 10-fold decrease in the lung-metastasis abilities of LM2 cells ( Figures 5A and 5B ). This effect was observed even at the early time points ( Figures  5A and 5B), suggesting that RBP2 controls extravasation and/or early seeding of lung metastasis in vivo. Histological analysis of the lungs isolated at necropsy confirmed that mice injected with RBP2 knockdown cells had fewer and smaller lesions in the lungs ( Figure 5C ).
To determine whether RBP2 more broadly affects tumor progression or metastasis to multiple organs in vivo, we performed stable RBP2 knockdown in the bone-selective 1833 breast cancer cell lines. Knockdown of RBP2 in 1833 cells had no significant effect on the ability of these cells to colonize the bone ( Figures 5D and S5B) . Knockdown of RBP2 also showed no effect on mammary tumor formation following orthotopic transplantation of LM2 cells into the mammary gland ( Figure 5E ). Altogether, these in vivo results are consistent with the observation that RBP2 regulates the expression of genes specific for lung metastasis.
To further validate our findings in a genetically engineered mouse model, we examined the effects of RBP2 loss on breast cancer progression and metastasis using MMTV-neu transgenic mice, a breast cancer mouse model in which >70% of mice with Scr si or Scr, scrambled siRNA, RBP2 si-1, RBP2 siRNA-1; RBP2 si-4, RBP2 siRNA-4; EV, empty vector plasmid; WT, wild-type RBP2 plasmid; HA-RBP2, HA-RBP2 plasmid; HA-RBP2 H483A, HA-RBP2 plasmid with H483A mutation; VSVG-RBP2, VSVG-RBP2 plasmids. A schematic map of VSVG-RBP2 plasmids is shown in Figure S4C . Error bars represent the SEM of three inserts. mammary tumors were previously shown to develop lung metastases (Guy et al., 1992) . These mice carry wild-type neu (the rat HER2 gene) under the control of the mouse mammary tumor virus (MMTV) promoter. We crossed the Rbp2 knockout mice with the MMTV-neu transgenic mice and monitored mammary tumor formation and lung metastasis. We found that Rbp2 knockout delayed mammary tumor formation in the MMTV-neu mice ( Figure 6A ), suggesting that RBP2 can contribute to mammary tumor development in this model. Lungs were obtained from mice when their primary mammary tumors were of similar size and reached approximately 1 cm 3 ( Figure S6 ). Similar to the results obtained from the experimental lung colonization model, the Rbp2 knockout mice showed a dramatic decrease in the number of lung-metastasis nodules and the incidence of lung metastasis (Figures 6B-6D) . Interestingly, in this model, most of the lung-metastasis nodules were located inside the blood vessels, suggesting that RBP2 can also mediate the survival and proliferation of breast cancer cells in the pulmonary vasculature. Taken together, our findings from the human cell line models, preclinical mouse models, and patient tumor samples strongly support a role for RBP2 as an epigenetic driver of metastasis.
DISCUSSION
By mining the gene-expression profiles of human mammary tumors, we identified a strong association of RBP2 expression with breast cancer metastasis. Consistent with this finding, we found that RBP2 is overexpressed in highly metastatic cell lines that were generated from both human and mouse breast tumors. We revealed that RBP2 has pleiotropic roles in invasion and metastasis, and linked RBP2 function to the regulation of several well-known genetic mediators of metastasis. Although recent studies highlighted the connection between epigenetic regulators and tumor metastasis, those studies were mostly limited to experiments using cancer cell lines or mouse xenograft models . Our study is bolstered by functional data from several preclinical mouse models, which demonstrate that RBP2 is a critical epigenetic mediator of metastasis and an ideal cancer target. Combined with our analysis of human patient data, these results provide a strong rationale for targeting RBP2 to treat invasive and metastatic breast cancer.
Using two independent bioinformatic pipelines, we showed that the RBP2 level correlated with an increased incidence of breast cancer metastasis. However, a recent report using GOBO (gene expression-based outcome for breast cancer online; Ringné r et al., 2011) showed that the RBP2 level correlated with increased relapse-free survival (Paolicchi et al., 2013) , although no functional experiments were performed to validate that result. This discrepancy could be due to the different cohort sizes and methods of analysis used. KaplanMeier Plotter for our analysis included more comprehensive gene-expression profiles of 2,977 nonredundant breast tumors (Gyö rffy et al., 2010) , whereas GOBO included 1,881 breast tumors (Ringné r et al., 2011) . In contrast to the one data-normalization step used by GOBO, our analysis also incorporated two :MMTV-neu mice (panels 2, 4, and 6), and the morphologies of the tumor cells are similar (panels 5 and 6). Scale bars, 500 mm (panels 1-4) and 100 mm (panels 5 and 6). See also Figure S6 . data-normalization steps and was independently validated. Therefore, the results from the previous study may have been more sensitive to data set inclusion and sample stratification. The inconsistency between these data sets requires further functional validation using cell-based assays and mouse models. Our extensive functional studies clearly validated our bioinformatic analysis, highlighting the importance of functional validation.
RBP2 has been implicated as an oncoprotein in various cancer types Sharma et al., 2010) . For example, it was reported that RBP2 amplification is found in approximately 15% of breast cancers (Hou et al., 2012) . We previously showed that RBP2 is critical for endocrine tumor formation in mice lacking Rb and menin tumor suppressors (Lin et al., 2011) . In this study, using two in vivo metastasis models, we demonstrated that knockdown or loss of RBP2 inhibits breast cancer metastasis to the lungs. In contrast, RBP2 is not required for bone metastasis by 1833 cells. These results highlight the critical role of a pleiotropic epigenetic regulator in directing the transcription program of tissue-specific metastasis. Although RBP2 knockdown did not affect the rate of primary tumor growth by LM2 cells in the orthotopic xenograft model, Rbp2 loss inhibited primary tumor formation in the MMTV-neu model. These results suggest that RBP2 likely regulates early stages of tumor progression when overexpressed early on in the mammary gland, or promotes a more amenable mammary tumor microenvironment for early tumorigenesis. Therefore, our studies highlight the importance of targeting RBP2 both in early tumorigenesis and in tumor metastasis. ER À breast cancer is an aggressive subtype of breast cancer that is often associated with rapid and frequent metastasis and poor patient outcome (Carey et al., 2010) . However, only a limited number of targeted therapeutic methods for patients with this type of breast cancer are currently under investigation in the clinic. Here, we demonstrated that RBP2 is critical for invasion and metastasis of ER À breast cancer cells. Suppression of tumor formation and metastasis by Rbp2 loss in the MMTV-neu model suggests that RBP2 is also critical for breast cancer metastasis in HER2 + patients, the majority of whom are also ER À . These findings are consistent with our results from human patient samples, which showed that RBP2 was strongly associated with increased metastasis in ER À patients. Taken together, these results support the requirement of RBP2 in aggressive breast cancers and provide a rationale for novel treatment methods targeting RBP2 in ER À and HER2 + patients.
Our gene-expression analyses showed that RBP2 is a pleiotropic positive regulator of lung-metastasis genes, suggesting that RBP2 is a critical epigenetic switch that enables tumor cells to metastasize by activating a constellation of genes. Contrary to the prevailing notion that RBP2 can only repress gene expression through histone demethylation, RBP2 has diverse activities in gene regulation and can activate gene expression (Benevolenskaya et al., 2005; Wang et al., 2009a) . Consistent with its role in gene activation, our mechanistic studies indicated that RBP2 promotes TNC expression and cell invasion via a demethylaseindependent mechanism. Similar to our findings, it was previously shown that Lid, the fly homolog of RBP2, has a demethylaseindependent function in dMyc-mediated cell growth and development . Furthermore, our results also indicated that the N-and C-terminal domains of RBP2 are required for regulation of TNC expression, and the N-terminal domains of RBP2 are required for cell invasion. The ARID domain located in the N terminus of RBP2 is involved in DNA binding (Tu et al., 2008) , while the LXCXE motif located in the C terminus of RBP2 interacts with Rb and p107 (Defeo-Jones et al., 1991; Kim et al., 1994) . Thus, our results suggest that DNA binding and recruitment of Rb or p107 by RBP2 may be required for activation of RBP2 target genes, such as TNC. In contrast, RBP2 demethylase activity was reported to promote proliferation of mouse embryonic fibroblasts (Lin et al., 2011) and growth and invasion of lung cancer cells (Teng et al., 2013) . Although demethylase inhibitors such as the small molecules we identified recently (Sayegh et al., 2013) could be used to suppress cancer progression in general, our results suggest that an alternative targeting strategy is needed to inhibit invasion and metastasis by breast cancer cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Transwell Invasion Assays MDA-MB-231 and 4T1 breast cancer cell series were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Retroviruses were generated by cotransfection of pLKO.1 plasmids carrying the indicated shRNAs with packaging plasmids into 293T cells as described previously . To generate RBP2 stable knockdown cell lines, LM2 cells were infected with the indicated viruses and selected with 1 mg/ml puromycin for 2 weeks. siRNA transfections were performed using RNAiMAX (Invitrogen). Plasmid transfections and plasmid/siRNA cotransfections were performed using Lipofectamine 2000 (Invitrogen). The shRNA sequences targeting RBP2 were as follows: sh-1, ccagacttacagggacactta; and sh-2, ccttgaaagaagccttacaaa. Scrambled control shRNA was described previously (Yang et al., 2007) . The siRNA targeting sequences of RBP2 were as follows: siRNA-1, gctgtacgagagtatacac; siRNA-2, cttctgtactgctgactgg; siRNA-3, gccaagaacattccagcct; and siRNA-4, gatagtagt tagaggctta, which targets the 3 0 UTR of RBP2. Scrambled siRNA was described previously (Beshiri et al., 2012) and luciferase siRNA was obtained from Dharmacon. The pcDNA3/HA-RBP2 construct was described previously (Benevolenskaya et al., 2005) and the H483A mutation was introduced by sitedirected mutagenesis as described previously . The pCI-neo/ VSVG-RBP2 constructs were described previously (Chan and Hong, 2001 ). The Transwell invasion assay was performed as described previously (Cheung et al., 2013) . Pictures of four random fields from each well were taken under the microscope at 103 magnification, and the number of cells on the basal side was counted. In the TNC rescue experiment, BSA and/or recombinant TNC protein (CC065; Millipore) were preincubated with the insert for 2 hr and added to the media when cells were seeded at a final concentration of 100 ng/ml.
Animal Studies
Female NOD.SCID mice (6-8 weeks old) were used for lung-metastasis and mammary fat pad tumor growth experiments. Male athymic nude mice (4-6 weeks old) were used for bone-metastasis experiments. For the lung-metastasis assay, 2 3 10 5 viable cells were resuspended in 0.1 ml saline and injected into the lateral tail vein. For the bone-metastasis assay, 1 3 10 5 viable cells were resuspended in 0.1 ml saline and injected into the left ventricle of the heart. Lung-or bone-metastatic colonization was monitored and quantified immediately after the injection and at the indicated time points using noninvasive bioluminescence, and validated at the endpoint by histological analysis as previously described (Bos et al., 2009; Lu et al., 2011; Nguyen et al., 2009b) . All values of luminescence photon flux were normalized to the value of the same mouse obtained immediately after injection of the cells. For the mammary fat pad tumor growth assay, 1 3 10 6 viable cells were resuspended in 0.1 ml of a 1:1 mixture of saline and Matrigel, and injected into the fat pads of the 4th mammary glands. Tumor weight was determined at the endpoint. 
Bioinformatic and Statistical Analysis
Kaplan-Meier Plotter analysis of histone-modifying enzymes in metastasisfree survival of breast cancer patients was performed by using the tool generated by Gyö rffy et al. (2010) . The following settings were used for the analysis: distant metastasis-free survival, autoselect best cutoff, 10 years follow-up threshold, ER status all, PR status all, lymph-node negative, grade all, and molecular subtype all. Multiple-testing-corrected p values of each probe were calculated by timing the original p value with the number of genes analyzed (n = 69). The results of these experiments are described in Figures  1A , 1B, S1A, S1C-S1E, S1G, and S1H and Table S1 . EMC286 cohort gene-expression data were downloaded from GSE2034 (Wang et al., 2005) and normalized using the robust multiarray average method within the R Affy package. For this cohort, the RBP2 probe 202040_s_at was selected for Kaplan-Meier metastasis-free survival analysis and correlation analysis. Samples with high, medium, and low RBP2 expression levels were clustered using the quartile or k-means as indicated in the figure legends. Metastasis-free survival plots and Cox univariate and multivariate metastasis-free survival analyses were performed using the R survival package. The Pearson correlation test was performed using the cor.test R function. The results of these experiments are described in Figures 1C, S1B , S1F, S1I, and S3B and Table S2 .
Triplicate total RNA samples were isolated from MDA-MB-231 cells 72 hr after transfection with siRNAs against RBP2 or luciferase control. Gene-expression profiling was performed by the Yale Center for Genome Analysis using the HumanHT-12 V3.0 Expression Beadchip Kit (BD-103-0203, Illumina). Nonnormalized gene-expression profiling data exported from Illumina Genome Studio were processed using the Lumi R package. The Limma R package was used to generate a differential expressed-gene list by comparing the average of two RBP2 knockdown (RBP2 siRNA-1 and siRNA-2) samples with the control knockdown (luciferase siRNA) samples. Using an adjusted p value of <0.05 and >1.5-fold difference as the cutoff, we found that 176 genes were upregulated and 212 were downregulated after RBP2 knockdown. The raw data were deposited in the NCBI Gene Expression Omnibus database under accession number GSE49119. The gene-expression profiles of the control knockdown and the average of two RBP2 knockdown cells were used for GSEA using GSEA v2.0 software. Gene sets were generated from published gene signatures (Bos et al., 2009; Kang et al., 2003; Minn et al., 2005 Minn et al., , 2007 . Statistical significance was assessed by comparing the enrichment score with enrichment results generated from 10,000 random permutations of the gene set. The log rank (Mantel-Cox) test was used for analysis of tumor-free survival curves of the MMTV-neu transgenic mice. A comparison of the number of metastatic nodules in lungs from wild-type and Rbp2 knockout mice was performed using the negative binomial model, and the t test was used for other statistical analyses.
Additional details regarding the methods used can be found in Supplemental Experimental Procedures.
ACCESSION NUMBERS
The raw data have been deposited in the NCBI Gene Expression Omnibus database under accession number GSE49119. 
